Nanotechnology, Biology, and Medicine



Editor-in-Chief
Lajos P. Balogh, PhD
Buffalo, NY
baloghl@prodigy.net

Managing Editor
Alice Landwehr
Tucson, Arizona
nanomedicine@cox.net

Publisher
Kate Williamson Elsevier Inc.
1600 John F. Kennedy Blvd., Suite 1800
Philadelphia, PA 19103
k.williamson@elsevier.com

ONLINE SUBMISSION SITE: http://ees.elsevier.com/nano/

Aims and Scope of the Journal

Nanomedicine: Nanotechnology, Biology, and Medicine (Nanomedicine: NBM) is an international, peer-reviewed journal. Each issue of Nanomedicine: NBM presents theoretical and experimental research results related to nanoscience and nanotechnology in life sciences, including Basic, Translational, and Clinical research, and commercialization of results. Article formats include Communications, Original Articles, Reviews, Perspectives, Technical and Commercialization Notes, and Letters to the Editor. In addition, regular features on our website will address commercialization, funding opportunities, and societal, Public Health, and ethical issues of nanomedicine. We invite authors to submit original manuscripts in these categories.

General Policies and Instructions for Authors

Article Types

COMMUNICATIONS: Communications are to disseminate new observations quickly to the scientific community. Length of communications should not exceed 1,200 words (3 pages), 4 figures, and 10 references. Communications enjoy priority in publishing.

RESEARCH ARTICLES: Research articles describe a full account about hypothesis-based research in nanomedicine. Length should not exceed 5,000 words (including title page, abstracts, text, references, tables, and figure legends), and the article should have no more than 6 figures in the main article. No more than 50 references should be cited. Theoretical articles include concept papers, mathematical modeling, etc.

SCIENTIFIC REVIEWS: Review articles of selected important topics in nanomedicine research. Length should not exceed 10,000 words (including title page, abstracts, text, references, tables, and figure legends), and the article should have no more than 15 figures. No more than 150 references should be cited,

PERSPECTIVES IN NANOMEDICINE: Invited articles or brief editorial comments that represent opinions of recognized leaders in nanomedicine research; length should not exceed 3000 words, and no more than 20 references should be cited

LETTERS TO THE EDITOR: Letters to the Editor serves the purpose to comment on research published in NNBM, including critical issues. Letters may not exceed 500 words with maximum 10 references and one illustration or table.

TECHNICAL AND COMMERCIALIZATION NOTES: Information regarding new technologies, business issues, commercialization of new products in the field, including Intellectual Property and patenting, Nanotechnology Law, etc. Length of technical notes should not exceed 1000 words (2 pages), 4 figures, and 10 references.

There are no limitations for length, figures and references in Supporting Information. TEMPLATE BASED PUBLISHING: Book Reviews, Meeting Announcements and Meeting Summaries may be published on the Journal website under a different heading and without typesetting. For Book Review and Meeting Summary proposals, please email the editor directly. For Meeting Announcements, please contact Kate Williamson.

The Journal will provide templates for material that will not receive typesetting. For questions, please contact Kate Williamson. Peer Review

All manuscripts will be evaluated for completeness and adherence to submission guidelines and will then undergo a peer-review process. Provisional or final acceptance is based on originality, scientific accuracy, relevance, clarity, and topical balance of the Journal. Authors should suggest the names (with contact information) of three potential reviewers for the manuscript. A request to submit a revised manuscript does not guarantee its acceptance, only that it will be reconsidered by the reviewers. Decisions will be communicated to the corresponding author by e-mail.

Conflict of Interest

Authors are required to acknowledge all funding sources that supported their work as well as all institutional or corporate affiliations of the authors. Each submission must also include a publishable statement on the title page disclosing any commercial associations, current and within the past five years, that might pose a potential, perceived, or real conflict of interest. These include grants, patent licensing arrangements, consultancies, stock or other equity ownership, advisory board memberships, or payments for conducting or publicizing the study.

When no competing interests are present, include a statement on the title page. The editor asks each reviewer to disclose any competing interests or to recuse oneself if a competing interest might interfere with one's objectivity. For more information, please see Elsevier's Conflict of Interest and Disclosure policies.

Ethical Considerations

Nanomedicine: NBM considers research and publication misconduct to be a serious breach of ethics, and will take such actions as necessary to address such misconduct. Authors should refer to the Committee on Publication Ethics (COPE) and the International Committee of Medical Journal Editors for full information. Authors are also encouraged to visit Elsevier's Ethical Guidelines for Journal Publication.

Plagiarism and duplicate submission are serious acts of misconduct. Plagiarism is defined as unreferenced used of published and unpublished ideas, and may occur at any stage of planning, researching, writing, or publication. Plagiarism takes many forms, from 'passing off' another's paper as the author's own paper, to copying or paraphrasing substantial parts of another's paper (without attribution), to claiming results from research conducted by others. Plagiarism in all its forms constitutes unethical publishing behavior and is unacceptable. Duplicate submission/publication occurs when two or more papers, without full cross-reference, share the same hypothesis, data, discussion points, or conclusions.

NIH Public Access Policy Compliance

To comply with the NIH Public Access Policy, Elsevier will deposit to PubMed Central (PMC) author manuscripts on behalf of authors reporting NIH funded research. The NIH's policy requires that NIH-funded authors submit to PubMed Central (PMC), or have submitted on their behalf, their peer-reviewed author manuscripts, to appear on PMC no later than 12 months after final publication. Elsevier will send to PMC the final peer-reviewed manuscript, which was accepted for publication and sent to Elsevier's production department, and that reflects any author-agreed changes made in response to peer-review comments. Elsevier will authorize the author manuscript's public access posting 12 months after final publication. Following the deposit by Elsevier, authors will receive further communications from the NIH with respect to the submission.

Note: Authors must declare their NIH funding (or the other funding bodies listed below) when completing the copyright transfer form.

Other Funding Body Policies

Elsevier has also worked with the following funding bodies to ensure that our authors can comply with their policies:

- Arthritis Research Campaign (UK)
- British Heart Foundation (UK)
- Cancer Research (UK)
- Chief Scientist Office
- Department of Health (UK)
- Howard Hughes Medical Institute (US)
- Medical Research Council (UK)
- Wellcome Trust (UK)

For full details on how these policies are implemented, please see complete information at: http://www.elsevier.com/wps/find/authorsview.authors/fundingbodyagreements

Requirements for studies involving live human or animal subjects:

For studies that involved human or animal research, indicate approval by the institution's human or animal subject review committee in the Methods section of the manuscript. Include an additional statement of the humane care of the animals with animal studies and a statement of informed consent or exempt classification by the IRB with human studies.

Submission of Manuscripts

Manuscripts must be submitted through the Nanomedicine:NBM online submission and review Web site ( http://ees.elsevier.com/nano ). All manuscripts submitted to the Journal must be original and must not have been previously published elsewhere or currently under consideration by another publication. In an accompanying letter, authors should state that the manuscript, or any part of it, is not and will not be submitted elsewhere for publication while under consideration by Nanomedicine:NBM.

Manuscript Preparation

Submission items include a cover letter, a list of suggested reviewers, the manuscript (including title page, abstract, manuscript text (divided into Background, Methods, Results, and Discussion), references, and table/figure legends), tables, and figures. Authors may also upload Supplementary Materials (see below). Revised manuscripts should also be accompanied by a unique file (separate from the covering letter) with responses to reviewers' comments.

The preferred order of files is as follows: cover letter, suggested reviewers, response to reviews (revised manuscripts only), manuscript file(s), table(s), figure(s). graphic abstract, supplementary material. Files should be labeled with appropriate and descriptive file names (e.g., SmithText.doc, Fig1.eps, Table3.doc, Supplementary.pdf). Upload text, tables and graphics as separate files. Do not import figures or tables into the text document. Pleasedo not upload your text as a PDF, but do upload text-based Supplementary Materials as a PDF.

Full-length article manuscripts should not exceed 6000 words in total length (including title page, abstract, text, references, tables, and figure legends), and should not contain more than 10 tables and figures. Manuscripts must be typed, double-spaced and assembled in this order: title page, abstract, text, acknowledgments, references, figure legends, tables and figures. Leave 1-inch margins on all sides. All manuscripts must conform to "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" ( http://www.icmje.org ).

PERMISSIONS: If any material has been published previously (figure, tables, etc), provide written permission from the copyright holder to use such material. Authors are responsible for obtaining permission and payment of any fees associated with reuse.

TITLE PAGE: The title page should contain these elements: full title, all authors' names, academic degrees, and affiliations; short title (not to exceed 50 characters, including spaces); name and complete address for corresponding author and address for reprints if different from correspondence; fax and telephone number and e-mail address; conflict of interest statement if applicable; all sources of support for research.

ABSTRACT: The abstract should not exceed 150 words and should summarize the content of the article. Insert 3 to 5 key words after the abstract.

New! GRAPHICAL ABSTRACTS: Authors are encouraged to submit a graphical abstract for their article. The image should summarize the contents of the paper in a concise, pictorial form designed to capture the attention of a wide readership and for compilation of databases. Graphical abstracts should be included as a separate file and submitted with figures; if the graphical abstract appears as a figure in the manuscript, please note this at the end of the abstract (i.e.: Graphical Abstract: Figure 2).

TEXT: For Communications and Original Articles, the text should include the headings Background, Methods, Results, and Discussion. Only essential data and descriptions shall be provided in the Methods and Results. All experimental details including synthetic and analytical procedures must be provided as a SUPPLEMENTARY MATERIALS (see below). All pages must be numbered. Abbreviations must be parenthetically notated at first mention in the text. Each table and figure must be mentioned in the text. Reports of studies on humans and animals must indicate that each study has been approved approved by an institutional review committee and the procedures followed are in accordance with institutional guidelines. Provide generic rather than trademarked names of drugs.

ACKNOWLEDGMENTS: The acknowledgments section recognizes substantive contributions of individuals. The Editorial Office must receive written, signed consent from each person recognized in the acknowledgments to be mentioned in the article because acknowledgment can imply endorsement of data and conclusions. . (See this sample of an Acknowledgement.) Upload each permission separately in the online system. Do not include statements of funding, conflicts, or other disclosures in the Acknowledgments; these must appear on the title page.

REFERENCES: Reference format should conform to that set forth in "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" ( http://www.icmje.org ) and journal abbreviations should conform to the style used in the Cumulated Index Medicus. Cite references, figures, and tables in numeric order according to the first mention in the text. Accuracy of reference data is the responsibility of the author. Verify all references against original sources. "In press" citations must have been accepted for publication and the name of the journal or book publisher must be included. The style of citation should be as follows:

Journals: authors' last names and initials; title of article; journal name; date; volume number, and inclusive pages (list all authors when six or fewer; when seven or more, list six and add et al):
1. Graeber GM, Gupta NC, Murray GF. Positron emission tomographic imaging with fluorodeoxyglucose is efficacious in evaluating malignant pulmonary disease. J Thorac Cardiovasc Surg 1999;117:719-27.
2. Lytle BW, Blackstone EH, Loop FD, Houghtaling PL, Arnold JH, Akhrass R, et al. Two internal thoracic artery grafts are better than one. J Thorac Cardiovasc Surg 1999;117:855-72.

Books: authors' last names and initials; chapter title, editor's name, book title, edition, city, publisher, date, and pages:
1. Mollnes TE. Analysis of in vivo complement activation: In: Herzenberg LA, Weir DM, Herzenberg LA, Blackwell C, editors. Weir's handbook of experimental immunology. Volume 78, 5th ed. Boston: Blackwell Science; 1997, p. 1-8.

Unpublished data and personal communications should be cited only in the text, not as a numbered reference. Authors wishing to cite unpublished material must have a letter of permission from the originator of the communication to do so. This letter should be submitted with the manuscript.

FIGURES: Figures must be of professional quality. When possible, please use first-generation artwork. Figures are encouraged in electronic format. Figures may be black and white line art, graphs, halftones (photographs), or color. Be sure that figures are submitted in .tif or .eps format. Line art (black lines on a white background) must have a minimum resolution of 1,000 dpi. Combination line art (eg, line art with gray fill patterns) must be created at 500 dpi. Black and white or color photographs must have a minimum resolution of 300 dpi.

Illustrations should be saved at the recommended resolution setting and sized as close to a column width (3 to 4 inches) as possible. Create figures in scale with each other to the extent possible. Avoid background gridlines and other formatting that do not convey information (eg, superfluous use of 3-dimensional formatting, background shadings). Use uniform lettering and sizing of all original artwork. As a general rule the lettering on the artwork should have a finished, printed size of 7 points. Smaller lettering will yield barely legible text. Recommended font choices include Arial, Helvetica, or Symbol. Labeling of multipart figures (eg, A, B, C...) should use capital letters only and should be done consistently, preferably using uppercase type (Arial, Helvetica or Universe, 11 or 12 points) in the lower-right corner of the figure. Avoid headings on the figure when possible. Additional information on preparation of electronic artwork can be found in the Artwork Instructions available at http://www.elsevier.com/authors. . For best results, please follow these guidelines carefully. There is no charge for publication of color illustrations.

TABLES: Table numbers should be Arabic, followed by a period and a brief title. Begin each table on a separate page. Use same size type as in text where possible. Supply a brief heading for each column. Do not use vertical lines between columns. Use horizontal lines above and below the column headings and at the bottom of the table only. Use extra space to delineate sections within the table. Abbreviations used in the table must be defined in a footnote to the table. Indicate footnotes in this order: .

New! SUPPLEMENTARY MATERIALS: Nanomedicine: NBM accepts supplementary data files to accompany the online article, allowing authors to support and enhance their papers. Supplementary materials may include experimental details, additional images, background datasets, video clips, etc. Experiments should be described in such detail that someone trained in the art could repeat the experiment or measurement. Please provide text-based data as a separate PDF file when submitting your manuscript. All supplementary materials are subject to peer review, but will not be edited by Nanomedicine: NBM . Supplementary materials will not be edited by Nanomedicine: NBM, and will be posted as provided by the authors. There are no limitations for length, figures and references in Supporting Materials.

VIDEOS: Authors are encouraged to submit videos that give readers a fuller understanding of the article. Supplementary movies or animation files that supplement a submitted article should be provided in one of the following preferred formats: .mpg, .mov, .avi, or .gif. All videos are subject to peer review. For more details, please visit http://www.elsevier.com/wps/find/authorsview.authors/movies_animations.

Within a week of acceptance, articles will be available on the www.nanomedjournal.com and ScienceDirect as Articles in Press, and will be indexed in PubMed/MEDLINE. Articles will then be copyedited and typeset, then compiled into issues available on the websites.

MEETING INFORMATION (announcements regarding upcoming nanomedicine conferences) and MEETING SUMMARIES will be posted on www.nanomedjournal.com separately from the scientific contents of the Journal.

OFFPRINTS: Offprint order forms will be sent to authors before articles are published. Reprints in quantity must be purchased from the Publisher.

Nanomedicine: NBM publishes COMMUNICATIONS, ARTICLES, REVIEWS, PERSPECTIVES AND LETTERS TO THE EDITOR in the categories below: Every issue contains at least one FEATURE ARTICLE selected by the EiC from any category.



Updated August 2009